Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Lipid Absorption

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluating inflammatory status to predict atrial fibrillation recurrence following ablation: The role of systemic immune-inflammation index.

World journal of cardiology·2025

Same author

Endothelial JCAD Worsens Acute Ischemic Stroke Outcomes by Enhancing Inflammation in Response to Ischemia/Reperfusion.

JACC. Basic to translational science·2025

Same author

Inflammation-Driven Plaque Erosion in Atherosclerosis: A Focus on Complement System Pathways.

Current atherosclerosis reports·2025

Same author

Artificial intelligence in gastroenterology: Ethical and diagnostic challenges in clinical practice.

World journal of gastroenterology·2025

Same author

Roadmap for alleviating the manifestations of ageing in the cardiovascular system.

Nature reviews. Cardiology·2025

Same author

Age- and sex-specific differences in myocardial sympathetic tone and left ventricular remodeling following myocardial injury.

Biology of sex differences·2025

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Ezetimibe/simvastatin.

Fabrizio Montecucco¹, Alessandra Quercioli, François Mach

¹University of Geneva, Department of Medicine, Switzerland. Fabrizio.montecucco@unige.ch

Expert Opinion on Drug Safety

|December 9, 2009

Summary

Ezetimibe/simvastatin therapy effectively lowers cholesterol and improves lipid profiles in hyperlipidemic patients. This combination demonstrates significant efficacy without increasing adverse events, offering a valuable treatment option.

Area of Science:

Cardiovascular Medicine
Pharmacology

Background:

Hyperlipidemia poses significant cardiovascular risks.
Ezetimibe and simvastatin are established lipid-lowering agents.
Combined ezetimibe/simvastatin therapy shows promise for managing cholesterol levels.

Purpose of the Study:

To evaluate the efficacy and safety of ezetimibe/simvastatin combination therapy.
To assess the potential of this combination in reducing atheroprogression.
To describe the molecular mechanisms behind its benefits in atherosclerosis.

Main Methods:

Review of clinical trials and meta-analyses.
Analysis of lipid profiles and adverse event data.
Exploration of molecular pathways related to atherosclerosis.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Experiment Videos

Last Updated: Jun 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Main Results:

Combined ezetimibe/simvastatin therapy rapidly reduces low-density lipoprotein cholesterol.
Improved lipid profiles were observed in clinical trials.
Greater lipid-lowering efficacy was not linked to increased adverse events.

Conclusions:

Ezetimibe/simvastatin is an effective option for hyperlipidemic patients.
It can be used as initial therapy or for patients not meeting lipid goals with statins alone.
Further studies may confirm long-term clinical benefits and safety.